Tag: radiotherapy
-
Andarix Pharmaceuticals Awarded Trademark for Tozaride by the US Patent and Trademark Office
Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it has been granted the US trademark for Tozaride by the United States Patent and Trademark Office.
-
Andarix Pharmaceuticals to Present at Neosynth Breast Cancer Conference
Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present at the Neosynth Breast Cancer Conference in Boston MA on April 24-25th 2019. The presentation will address the ability of theranostic technology to provide personalized medicine to diagnose and treat breast cancer. The three main types…
-
Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at the Society of Nuclear Medicine Meeting
ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of Tozaride, the company’s lead candidate in neuroendocrine lung cancer patients. The abstract is entitled “Targeted Clinical Study…
-
Andarix Pharmaceuticals to Present at the Rare Disease Innovation Summit
Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced today that its Chief Executive Officer, Chris Adams, will present at the Rare Disease Innovation Summit set to take place in Cambridge , MA June 19-20.
-
Andarix Pharmaceuticals to Present at Regulatory Pathways Summit Conference
Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Innovative Regulatory Pathways Summit in Washington, DC. January 29-30, 2018.
-
A Billion Dollar Drug Using a Virtual Business Model
Chris Adams, CEO, Andarix, explains how industry can leverage technology to make the drug development process more efficient
-
Andarix Pharmaceuticals Selected to Present at Lung Cancer Summit in Boston, MA
Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Precision Lung Cancer Summit in Boston, Massachusetts July 25-26, 2017. Conference location and agenda information are available at the Precision Lung Cancer Conference.
-
Andarix Pharmaceuticals and Wuxi Fortune Pharmaceuticals Sign Drug Deal for China Market
Andarix Pharmaceuticals Inc, a clinical stage company, and Wuxi Fortune Pharmaceuticals announced today the signing of an agreement to develop and commercialize a drug to treat lung and other cancers. As part of the agreement Wuxi Fortune will have certain rights to the China market for Tozaride, a targeted peptide therapy. Wuxi Fortune and Andarix…
-
Andarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study
In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using Rhenium Re 188 P2045, a radiolabeled somatostatin analog. 25 Patients received the imaging dose of 10uCi of Re188 and 265ng of peptide by intravenous injection. Patients were selected based on high SSTR expression levels…
-
Andarix and Tulane University Collaborate to Further Research on Mediators of Cancer Cell Signaling
ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for cancers announced today that the Company has entered into an agreement with Tulane University, an institution at the forefront of modern medical innovation, to license the technology and intellectual property concerning Notch Influencing Molecules.